IL219504A - Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion - Google Patents

Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion

Info

Publication number
IL219504A
IL219504A IL219504A IL21950412A IL219504A IL 219504 A IL219504 A IL 219504A IL 219504 A IL219504 A IL 219504A IL 21950412 A IL21950412 A IL 21950412A IL 219504 A IL219504 A IL 219504A
Authority
IL
Israel
Prior art keywords
medicaments
preparation
pharmaceutical compositions
same
heart failure
Prior art date
Application number
IL219504A
Other languages
English (en)
Hebrew (he)
Other versions
IL219504A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL219504A0 publication Critical patent/IL219504A0/en
Publication of IL219504A publication Critical patent/IL219504A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL219504A 2009-11-03 2012-04-30 Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion IL219504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (2)

Publication Number Publication Date
IL219504A0 IL219504A0 (en) 2012-06-28
IL219504A true IL219504A (en) 2016-09-29

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219504A IL219504A (en) 2009-11-03 2012-04-30 Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion

Country Status (13)

Country Link
US (1) US8859571B2 (enExample)
EP (1) EP2501233B1 (enExample)
JP (1) JP5836963B2 (enExample)
KR (1) KR101736521B1 (enExample)
CN (1) CN102711474B (enExample)
AU (1) AU2010315361B2 (enExample)
BR (1) BR112012010524A2 (enExample)
CA (1) CA2779989A1 (enExample)
EA (1) EA021439B1 (enExample)
ES (1) ES2523465T3 (enExample)
IL (1) IL219504A (enExample)
MX (1) MX2012005155A (enExample)
WO (1) WO2011056740A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6,7-二(2-甲氧基乙氧基)喹唑啉的制备方法
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
CN105849044B (zh) 2013-12-26 2018-10-26 埃克森美孚研究工程公司 Zsm-48晶体的合成
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CN114521196A (zh) 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
EP4405360A4 (en) 2021-09-23 2025-08-20 Erasca Inc POLYMORPHIC FORMS OF EGFR INHIBITOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤

Also Published As

Publication number Publication date
KR20120112441A (ko) 2012-10-11
ES2523465T3 (es) 2014-11-26
AU2010315361B2 (en) 2014-06-12
BR112012010524A2 (pt) 2017-12-12
EP2501233A4 (en) 2013-06-19
EP2501233A1 (en) 2012-09-26
JP2013510155A (ja) 2013-03-21
EA201290243A1 (ru) 2012-12-28
CA2779989A1 (en) 2011-05-12
MX2012005155A (es) 2012-08-31
CN102711474B (zh) 2014-09-10
US8859571B2 (en) 2014-10-14
AU2010315361A1 (en) 2012-05-24
EA021439B1 (ru) 2015-06-30
US20120220588A1 (en) 2012-08-30
WO2011056740A1 (en) 2011-05-12
IL219504A0 (en) 2012-06-28
CN102711474A (zh) 2012-10-03
KR101736521B1 (ko) 2017-05-16
EP2501233B1 (en) 2014-09-24
JP5836963B2 (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL250740A0 (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL253000A0 (en) Tricyclic pyrazolyl compounds, their use for the preparation of drugs for the treatment of cancer and pharmaceutical preparations containing them
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
PL2731947T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL217490A (en) History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines
IL221146A (en) History of Pyridine 2,5- Two-Converted, Pharmaceutical Preparations Containing Them, and Their Use in the Preparation of Drugs for the Prevention and Treatment of Cancer
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL215799A (en) Quinazolone compounds, pharmaceuticals containing them and their uses
IL214098A (en) Derivatives of 2– (pyrolidine – 2 – il) - h1– benzimidazole, pharmaceutical preparations containing them and their use in the preparation of drugs
IL220129A (en) History of benzamide, preparations containing them and their use in the treatment of cancer
IL214309A (en) Preserved pyridines, pharmaceuticals containing them and their use in the preparation of medicines
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
IL216006A (en) Processed aromatic compounds, pharmaceutical preparations including them and their use in the manufacture of pharmaceuticals

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees